CA2674440A1 - Methods for improved stability of steroid derivatives - Google Patents
Methods for improved stability of steroid derivatives Download PDFInfo
- Publication number
- CA2674440A1 CA2674440A1 CA002674440A CA2674440A CA2674440A1 CA 2674440 A1 CA2674440 A1 CA 2674440A1 CA 002674440 A CA002674440 A CA 002674440A CA 2674440 A CA2674440 A CA 2674440A CA 2674440 A1 CA2674440 A1 CA 2674440A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- acetoxy
- diene
- alkyl
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003431 steroids Chemical class 0.000 title description 12
- 238000000034 method Methods 0.000 title description 11
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims description 66
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- -1 alkoxy ester Chemical class 0.000 claims description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000000524 functional group Chemical group 0.000 claims description 20
- 125000004423 acyloxy group Chemical group 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 230000001911 anti-progestational effect Effects 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 201000010260 leiomyoma Diseases 0.000 claims description 6
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 5
- 201000009273 Endometriosis Diseases 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 206010027191 meningioma Diseases 0.000 claims description 5
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- 125000005910 alkyl carbonate group Chemical group 0.000 claims description 4
- 230000002124 endocrine Effects 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 210000004914 menses Anatomy 0.000 claims description 3
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 9
- 239000012458 free base Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000007900 aqueous suspension Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 201000007954 uterine fibroid Diseases 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000012053 oil suspension Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- SQWBBFUHZKCYCT-YSTOQKLRSA-N (8s,13s,14s,17s)-17-acetyl-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 SQWBBFUHZKCYCT-YSTOQKLRSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- DQCVSBBPPYWCRG-UHFFFAOYSA-N 2-acetyloxy-2-formyloxy-2-[heptanoyloxy(propanoyloxy)amino]acetic acid Chemical compound CCCCCCC(=O)ON(C(C(=O)O)(OC=O)OC(=O)C)OC(=O)CC DQCVSBBPPYWCRG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- VMWJCFLUSKZZDX-UHFFFAOYSA-N n,n-dimethylmethanamine Chemical compound [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- CSUXYWBSYIKFBC-KTTGPIHOSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 CSUXYWBSYIKFBC-KTTGPIHOSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 229940106582 estrogenic substances Drugs 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940102253 isopropanolamine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical group C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003408 postcoitus contraceptive agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compositions with improved stability comprising a pharmaceutically acceptable salt of 11-(4-aminophenyl)-19-no.phi.regna-4,9(10)-diene- 3,20-dione derivatives are provided
Description
07189.0054.PZUSOO
METHODS FOR IMPROVED
STABILITY OF STEROID DERIVATIVES
FIELD OF THE INVENTION
[0001] The present invention relates generally to compositions comprising steroids and, in particular, to compositions with potent antiprogestational activity, minimal antiglucocorticoid activity and improved stability, comprising a 19-norprogesterone I
derivative. The present invention also relates to methods using the compositions.
BACKGROUND OF THE INVENTION
METHODS FOR IMPROVED
STABILITY OF STEROID DERIVATIVES
FIELD OF THE INVENTION
[0001] The present invention relates generally to compositions comprising steroids and, in particular, to compositions with potent antiprogestational activity, minimal antiglucocorticoid activity and improved stability, comprising a 19-norprogesterone I
derivative. The present invention also relates to methods using the compositions.
BACKGROUND OF THE INVENTION
[0002] There have been numerous attempts over the past few decades to prepare steroids with antihormonal activity. It has been generally recognized for some years, that antiprogestational steroids would find wide applicability in population control, while antiglucocorticoids would be extremely valuable in the treatment of, for example, Cushing's syndrome and other conditions characterized by excessive endogenous production of cortisone.
[0003] For purposes of contraception, it would be advantageous to have compounds which possess antiprogestational activity without (or with minimal) antiglucocorticoid activity. Although there have been a number of attempts to modify the mifepristone structure in order to obtain separation of the antiprogestational activity from the antiglucocorticoid activity, this goal has not yet been fully achieved. As such, there remains a need in the art for the development of new formulations comprising steroids which possess antiprogestational activity with minimal antiglucocorticoid activity.
[0004] U.S. Patents 6,861,415 and 6,900,193, both incorporated herein by reference, disclose new compounds which possess antiprogestational activity with minimal antiglucorticoid activity. The compounds are steroid derivatives, and more specifically they are structural modifications of 19-norprogesterone I, such as 17-a-substituted-ll-0-substituted-4-aryl and 21-substituted 19-norpregnadienedione, and are poorly soluble in water. Therefore, a need remains in the art to develop formulations comprising the steroid derivatives with increased stability and improved bioavailability.
SUMMARY OF THE INVENTION
100051 The present invention provides new formulations with potent antiprogestational activity, minimal antiglucocorticoid activity and improved stability.
SUMMARY OF THE INVENTION
100051 The present invention provides new formulations with potent antiprogestational activity, minimal antiglucocorticoid activity and improved stability.
[0006] More particularly, the present invention provides compositions comprising a pharmaceutically acceptable salt of a compound having the following general formula I:
R' O
R4 ,o R3 X
R' O
R4 ,o R3 X
[0007] Wherein: R' is a basic functional group upon which a salt may be prepared, preferably comprising a nitrogen, including, but not limited to, -N(CH3)2, -NHCH3, -NC4H8, -NC5H,o, -NC4H8O, -O(CH2)2N(CH3)2, -O(CH2)2NC4H8 and -O(CHZ)2NC5H1 o; R2 is a functional group including, but not limited to, hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy (e.g., methoxy, ethoxy, vinyloxy, ethynyloxy, cyclopropyloxy, etc.), acyloxy (e.g., formyloxy, acetoxy, propionyloxy, heptanoyloxy, glycinate, etc.), alkylcarbonate, cypionyloxy, S-alkyl, -SCN, S-acyl and -OC(O)R6, wherein R6 is a functional group including, but not limited to, alkyl (e.g., methyl, ethyl, etc.), alkoxyalkyl (e.g., --CH2OCH3) and alkoxy (-OCH3);
R3 is a functional group including, but not limited to, alkyl (e.g., methyl, methoxymethyl, etc.), hydroxy, alkoxy (e.g., methoxy, ethoxy, methoxyethoxy, vinyloxy, etc.), and acyloxy; R4 is a functional group including, but not limited to, hydrogen and alkyl;
and X is a functional group including, but not limited to, =0 and =N-ORS, wherein R5 is a member selected from the group consisting of hydrogen and alkyl and with the proviso that when R' is -N(CH3)2, RZ is methoxy, R3 is acetoxy, R4 is methyl and X
is =0, the salt is not an HC1 or an HBr salt.
R3 is a functional group including, but not limited to, alkyl (e.g., methyl, methoxymethyl, etc.), hydroxy, alkoxy (e.g., methoxy, ethoxy, methoxyethoxy, vinyloxy, etc.), and acyloxy; R4 is a functional group including, but not limited to, hydrogen and alkyl;
and X is a functional group including, but not limited to, =0 and =N-ORS, wherein R5 is a member selected from the group consisting of hydrogen and alkyl and with the proviso that when R' is -N(CH3)2, RZ is methoxy, R3 is acetoxy, R4 is methyl and X
is =0, the salt is not an HC1 or an HBr salt.
[0008] The compositions may possess potent antiprogestational activity with minimal antiglucocorticoid activity in combination with improved stability. Therefore, the compositions may be suitable for long term use in the treatment of human endocrinological disorders or other conditions in steroid-sensitive tissues.
Specific conditions for treatment include, but are not limited to, endometriosis, dysmenorrhea, uterine leiomyoma, uterine fibroid, meningioma and metastatic breast cancer.
Other uses include, but are not limited to, contraception, including emergency post-coital contraception and inducement of cervical ripening.
Specific conditions for treatment include, but are not limited to, endometriosis, dysmenorrhea, uterine leiomyoma, uterine fibroid, meningioma and metastatic breast cancer.
Other uses include, but are not limited to, contraception, including emergency post-coital contraception and inducement of cervical ripening.
[0009] Also provided is the use of any of the compositions of the present invention in the manufacture of a medicament for treatment of human endocrinological disorders or other conditions in steroid-sensitive tissues as described herein, including but not limited to, endometriosis, dysmenorrhea, uterine leiomyoma, uterine fibroid, meningioma and metastatic breast cancer.
DETAILED DESCRIPTION OF THE INVENTION
DETAILED DESCRIPTION OF THE INVENTION
[0010] A composition is provided comprising a steroid derivative with the following general formula I:
R' O
X
R' O
X
[0011] In Formula I, R' is a basic functional group upon which a salt may be prepared, preferably comprising a nitrogen, including, but not limited to, -N(CH3)2.
-NHCH3, -NC4H8, NC5H1o, -NC4H8O, -O(CH2)2N(CH3)2, -O(CH2)2NC4H8 and -O(CH2)2NC5Hj0; R2 is a functional group including, but not limited to, hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy (e.g., methoxy, ethoxy, vinyloxy, ethynyloxy, cyclopropyloxy, etc.), acyloxy (e.g., formyloxy, acetoxy, propionyloxy, heptanoyloxy, glycinate, etc.), alkylcarbonate, cypionyloxy, S-alkyl, -SCN, S-acyl and -OC(O)R6, wherein R6 is a functional group including, but not limited to, alkyl (e.g., methyl, ethyl, etc.), alkoxyalkyl (e.g., -CH2OCH3) and alkoxy (-OCH3);
R3 is a functional group including, but not limited to, alkyl, hydroxy, alkoxy and acyloxy;
R4 is a functional group including, but not limited to, hydrogen and alkyl;
and X is a functional group including, but not limited to, =0 and =N-OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl, with the proviso that when R] is N(CH3)2, R2 is methoxy, R3 is acetoxy, R4 is methyl and X is =0, the salt is not an HC1 or an HBr salt.
[00121 Thus, compositions of the present invention comprise a compound of general formula I which is capable of forming a salt when the compound is reacted with a suitable acid. Preferably, a compound of general formula I comprises a basic functional group attached at the 4 position of the phenyl group located at the 11(3 position of the compound (i.e., the R' position); however, compounds of general formula I comprising a basic functional group attached at any position are within the scope of the invention so long as a salt of the compound may be prepared. In addition to the basic functional groups listed above, other suitable basic functional groups for R' upon which a salt may be prepared include, without limitation, methylamine, dimethylamine, ethylamine, diethylamine, ethylmethylamine, isopropylamine, diisopropylamine, n-butylamine, ethanolamine, diethanolamine, methylethanolamine, isopropanolamine, diisopropanolamine, ethyleneimine, ethylenediamine, pyridine and morpholine functional groups.
100131 The term "alkyl" refers to a branched, unbranched, monovalent hydrocarbon radical having from 1-12 carbons. When the alkyl group has from 1-6 carbon atoms, it may be referred to as a "lower alkyl." Representative alkyl radicals include, for example, methyl, ethyl, n-propyl, i-propyl, 2-propenyl (or allyl), n-butyl, t-butyl, i-butyl (or 2-methylpropyl), etc. As used herein, the term alkyl encompasses "substituted alkyls." A substituted alkyl refers to alkyl further containing one or more functional groups such as lower alkyl, aryl, aralkyl, acyl, halogen (i.e., alkylhalos, e.g., CF3), hydroxy (e.g., hydroxymethyl), amino, alkylamino, acylamino, acyloxy, alkoxy (e.g., methoxymethyl), mercapto and the like. These groups may be attached to any carbon atom of the lower alkyl moiety.
[00141 The term "alkoxy" may refer to a -OR group, where R is a lower alkyl, substituted lower alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl. Suitable alkoxy radicals include, for example, methoxy, ethoxy, phenoxy, t-butoxy (e.g., methoxyethoxy, methoxymethoxy, etc.), etc.
[0015] The term "acyloxy" may refer to an organic radical derived from an organic acid by the removal of a hydrogen. The organic radical can be further substituted with one or more functional groups such as alkyl, aryl, aralkyl, acyl, halogen, amino, thiol, hydroxy, alkoxy, etc. An example of such a substituted organic radical is glycinate (e.g., --OC(O)CHzNHz). Suitable acyloxy groups include, for example, acetoxy, i.e., CH3COO-, which may be derived from acetic acid, formyloxy, i.e., H(CO)O-, which may be derived from formic acid and cypionyloxy, which may be derived from 3-cyclopentylpropionic acid.
[0016] The term "halogen" may refer to fluorine, bromine, chlorine and iodine atoms.
The term "hydroxyl" may refer to the group -OH. The term "acyl" may denote groups -C(O)R, where R is alkyl or substituted alkyl, aryl or substituted aryl as defined herein. The term "aryl" may refer to an aromatic substituent which may be a single ring or multiple rings which are fused together, linked covalently, or linked to a common group such as an ethylene or methylene moiety. The aromatic ring(s) may include phenyl, naphthyl, biphenyl, diphenylmethyl, 2,2-diphenyl-l-ethyl, and may contain a heteroatom, such as thienyl, pyridyl and quinoxalyl. The aryl group may also be substituted with halogen atoms, or other groups such as nitro, carboxyl, alkoxy, phenoxy, and the like. Additionally, the aryl group may be attached to other moieties at any position on the aryl radical which would otherwise be occupied by a hydrogen atom (such as 2-pyridyl, 3-pyridyl and 4-pyridyl).
[0017] The term "alkyl carbonate" may refer to the group -OC(O)OR, where R is alkyl, substituted alkyl, aryl, or substituted aryl as defined herein.
[0018] The term "S-alkyl" may refer to the group -SR, where R is lower alkyl or substituted lower alkyl. The term "S-acyl" may refer to a thioester derived from the reaction of a thiol group with an acylating agent. Suitable S-acyls include, for example, S-acetyl, S-propionyl and S-pivaloyl. S-acyl may refer to such thioesters regardless of their method of preparation. The terms "N-oxime" and "N-alkyloxime"
may refer to the group =N-OR5, wherein R5 is, for example, hydrogen (N-oxime) or alkyl (N-alkyloxime). The oximes can consist of the syn-isomer, the anti-isomer or a mixture of both the syn- and anti-isomers.
100191 Representative compounds within Formula I, include those in which R' is --N(CH3)2; those in which R2 is hydrogen, halogen or alkoxy; those in which R3 is acyloxy; those in which R4 is alkyl (e.g., methyl and ethyl); and those in which X is =0 and =N-OR5, wherein R5 is hydrogen or alkyl. Additional compounds include those in which R' is --N(CH3)2; R2 is halogen; R3 is acyloxy; and R4 is alkyl, such where R2 is F, Br or Cl; and R4 is methyl. Also included are compounds in which R' is -N(CH3)2; R2 is alkyl; R3 is acyloxy; R4 is alkyl; and X is =0. Also included are compounds in which R' is --N(CH3)2; R2 is alkoxy; R3 is acyloxy; R4 is alkyl;
and X
is =0. Additional compounds are those in which R 2 is methoxy or ethoxy; and R3 is acetoxy or methoxy. Also included are compounds in which R' is -N(CH3); R 2 is hydroxy; R3 is acyloxy; R4 is alkyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R2 and R3 are both acyloxy; R4 is alkyl; and X is =0.
Additional compounds are those in which R2 and R3 are both acetoxy. Also included are compounds in which R' is -N(CH3)2; R 2 is S-acyl; R3 is hydroxy or acyloxy; R4 is alkyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R
2 is cypionyloxy; R3 is acetoxy; R4 is alkyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R 2 is methoxy; R3 is acetoxy; R4 is alkyl; and X is =0 and =N-ORS, wherein R5 is, for example, hydrogen or alkyl (e.g., methyl, ethyl, etc.).
Also included are compounds in which R' is -N(CH3)2; R2 and R3 are both acetoxy;
R4 is alkyl; and X is =0 and =N-ORS, wherein RS is, for example, hydrogen or alkyl (e.g., methyl, ethyl, etc.).
[0020] Exemplar compounds include, but are not limited to, 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-methoxy-l9-norpregna-4,9(10)-diene-3,20-dione (CDB-4124) with the following structural formula:
i H3 OMe HC~N
3 OAc O
with the proviso that salts of CDB-4124 are not HC1 or HBr acid salts.
100211 Another exemplar compound is 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione (CDB-2914) with the following structural formula:
H C~N
3 OAc O
[0022] Other exemplar compounds include, but are not limited to, 17a-acetoxy-chloro-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione;
17a-acetoxy-2l-bromoro-11 [3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17-,21-diacetoxy-11(3-(4-N,N-dimethylaminophenyl) 19-norpregna-4,9-diene-3,20-dione; 17a-hydroxy-21-acetylthio-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21 -acetylthio-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-ethoxy-11(3-(4N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-methyl-11(3-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione;
17a-acetoxy-21-methoxy-11(3-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21 -ethoxy-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-(3'-cyclopentylpropionyloxy) 11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-hydroxy-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione;
17a,21-diacetoxy-11 [3-(4-N,N-dimethylaminophenyl) 9-norpregna-4,9-diene-3,20-dione 3-oxime; 17a-acetoxy-21-methoxy-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,2-dione 3-oxime; 17a-acetoxy-11(3-[4-(N-methylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; and 17a,21-diacetoxy-11 [3-[4-(N-methylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione.
[0023] Also included are those compounds in which R' is -N(CH3)2, -NC4H8, --NC4H1 o, -NC4HgO, -O(CH2)2N(CH3)2, -O(CH2)2NC4H8, --O(CH2)2NC3H1 o, and -O(CH2)2NCSHjo; those in which R 2 is hydrogen, alkyloxy, alkoxy, -SAc, -SCN, -OC(O)CH2N(CH3)2, and -OC(O)R6, wherein R6 is a functional group including, but not limited to, alkyls (e.g., -CH2CH3), alkoxy esters (e.g., -CHzOMe) and alkoxys (e.g., -OCH3); those in which R3 is alkyl, alkoxy, acyloxy and hydroxy;
those in which R4 is alkyl (e.g., methyl and ethyl); and those is which X is =0 or =N-OR5, wherein R5 is hydrogen or alkyl. Also preferred are compounds in which R' is -N(CH3)2; R2 is hydrogen; R3 is methoxymethyl; R4 is methyl; and X is =0.
Also included are compounds in which R' is -N(CH3)2; R 2 is hydrogen; R3 is -OC(O)H, -OC(O)CH2CH3 or -OC(O)C6H13; R4 is methyl; and X is =0. Also included are compounds in which R' is -NC4Hs, -NC5H~o, or -NC4HgO; R2 is hydrogen; R3 is acetoxy; R4 is methyl; and X is =0. Also included are compounds in which R' is -N(CH3)2 or NC5Hio; R2 is hydrogen; R3 is methoxy; R4 is methyl;
and X is =0. Also included are compounds in which R' is --NC5Hio; R2 and R3 are both acetoxy; R4 is methyl; and X is =0. Also included are compounds in which R' is -NC5HI o or --O(CH2)2N(CH3)2; R 2 is methoxy; R3 is acetoxy; R4 is methyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R2 is -OC(O)CH2CH3, --OC(O)OCH3, -OC(O)OCH2OCH3, -OCH=CH2, -OC(O)CH2N(CH3)2 or -SCN; R3 is acetoxy; R4 is methyl; and X is =0. Also included are compounds in which Ri is --N(CH3)2; R2 is -OC(O)H; R3 is -OC(O)H; R4 is methyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R2 is -OC(O)H; R3 is hydroxy; R4 is methyl; and X is =0. Also included are compounds in which R' is -NC5Hlo; R2 is hydrogen; R3 is acetoxy; R4 is methyl; and X is =N-ORS, wherein is hydrogen. Also included are compounds in which R' is -N(CH3)2 or -NC5Hio;
R 2 is hydrogen or methoxy; R3 is methoxy or ethoxy; R4 is methyl; and X is =N-----ORS, wherein RS is hydrogen.
[0024] Exemplar compounds also include, but are not limited to, 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-methoxy-l9-norpregna-4,9(10)-diene-3,20-dione;
17a-formyloxy-11(3-[4-(N,N-diethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-propionoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-heptanoyloxy-11 R-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-methoxymethyl-11(3-[4-N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-(4-N-pyrrolidinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-(4-N-piperidinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-(4-N-morpholinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-methoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-methoxy-11 P-(4-N-piperidinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a,21-diacetoxy-11(3-(4-N-piperidinophenyl)-norpregna-4,9-diene-3,20-dione; 17a,21-dimethoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a,21-dimethoxy-11(3-(4-N-pyrrolidinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a,21-dimethoxy-11(3-(4-N-piperidinophenyl) 19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-{4-[2'-(N,N-dimethylamino)ethoxy]phenyl } -21-methoxy-l9-norpregna-4,9-diene-3,20-dione; 17a,21-diformyloxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-propionyloxy-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-(2'-methoxyacetyl)oxy-l9-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-hydroxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione-2l-methyl carbonate; 17a-acetoxy-110-[4-(N,N-dimethylamino)phenyl]-21-(1'-ethenyloxy)-19-norpregna-4,9-diene-3,20-dione;
17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-(2'-N,N-dimethylamino)acetoxy-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-thiocyanato-l9-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-(4-N-piperidinophenyl)-19-norpregna-4,9-diene-3,20-dione 3-oxime; 17a-methoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione 3-oxime; 17a-methoxy-11 [1-(4-N-piperidinophenyl)-19-norpregna-4,9-diene-3,20-dione 3 -oxime;
and 17a,21-dimethoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione 3-oxime.
100251 The stability of a compound having general formula I may be significantly increased when the compound is in the form of a salt. A composition is provided comprising a pharmaceutically acceptable salt of a compound of formula I and optionally a pharmaceutically acceptable carrier.
100261 In practice, the use of the salt form inherently amounts to use of the free base form. Accordingly, acids which are suitable to prepare the salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial pharmaceutical effects of these compounds in the free base are not vitiated by side effects ascribable to the anions. The compounds of general formula I may be regenerated from the salts by the application or adaptation of known methods. For example, the compounds can be regenerated from their acid addition salts by treatment with an alkali, e.g., sodium bicarbonate solution.
[0027] The salts can be prepared in situ during the final isolation and purification of a compound of general formula I or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, halide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactiobionate, laurylsulphonate salts and the like (See, for example, S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 66:1-19, 1977, the contents of which are hereby incorporated herein by reference). For example, the salts may be prepared either by dissolving the free base in aqueous or aqueous-alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
[0028] The term "pharmaceutically acceptable salt" refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of general formula I.
[0029] Compositions are provided comprising a pharmaceutically acceptable salt of a compound of general formula I. It is expected that salts of a compound of general formula I will have increased stability relative to an equivalent amount of the free base form of the compound under equivalent conditions. Thus, it is expected that compositions of the instant invention will have increased resistance to chemical modification. The stability of a pharmaceutically acceptable salt of a compound of general formula I may be enhanced by at least 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 percent or more relative to an equivalent amount of the free base form of the same compound under equivalent conditions.
[0030] A typical parameter of stability is shelf life, which is defined as the time period during which a drug product is expected to remain within the approved shelf life specification. Accelerated testing may be performed for a 6-month period at 40 degrees C and 75% relative humidity. Under these conditions, a change in drug concentration of about 5% from the initial assay values is considered significant. It is expected that compositions comprising pharmaceutically acceptable salts of compounds of general formula I will exhibit an increased shelf life relative to equivalent compositions comprising the free base form of the same compounds under equivalent conditions.
[0031] Stability, as used herein, refers to the ability to detect the active ingredient (i.e., a compound of general formula I), in a composition, typically by HPLC, after storage interval under predetermined conditions of temperature and humidity.
Although HPLC is preferred, any method for detecting the active ingredient capable of identifying chemical modification and/or change in concentration of the active ingredient may be used.
[0032] Also provided is a method for increasing the stability of a compound of general formula I by reacting the compound with a suitable acid to form a pharmaceutically acceptable salt.
[0033] The compositions may possess potent antiprogestational activity and minimal antiglucocorticoid activity, combined with improved stability, which may render these compositions suitable for oral administration.
100341 The compositions can be advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningioma; to treat uterine leiomyonas, to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; to induce cervical ripening, for hormone therapy; and for contraception.
[0035] The compositions having antiprogestational activity may also be characterized by antagonizing the effects of progesterone. As such, the compositions may be of particular value in the control of hormonal irregularities in the menstrual cycle, for controlling endometriosis and dysmenorrhea, and for inducing menses. In addition, the compositions can be used as a method of providing hormone therapy either alone or in combination with estrogenic substances in postmenopausal women, or in women whose ovarian hormone production is otherwise compromised.
[0036] Moreover, the compositions can be used for control of fertility during the whole of the reproductive cycle. For long-term contraception, the compositions can be administered either continuously or periodically depending on the dose. In addition, the compositions may be of particular value as post-coital contraceptives, for rendering the uterus inimical to implantation, and as "once a month"
contraceptive agents.
100371 A further important utility for the compositions lies in their ability to slow down growth of hormone-dependent tumors and/or tumors present in hormone-responsive tissues. Such tumors include, but are not limited to, kidney, breast, endometrial, ovarian, and prostate tumors, e.g., cancers, which may be characterized by possessing progesterone receptors. In addition, such tumors include meningiomas.
Other utilities of the compositions include the treatment of fibrocystic disease of the breast and uterine.
100381 The compositions can be administered to any warm-blooded mammal such as humans, domestic pets, and farm animals. Domestic pets include dogs, cats, etc. Farm animals include cows, horses, pigs, sheep goats, etc.
[0039] The amount of active ingredient that can be combined with an optimal carrier material to produce a single dosage form will vary depending upon the disease treated, the mammalian species, and the particular mode of administration. For example, a unit dose may comprise between 0.1 milligram and 1 gram of the active ingredient or between 0.001 and 0.5 grams. However, the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion;
other drugs which have previously been administered; and the severity of the particular disease undergoing therapy.
-NHCH3, -NC4H8, NC5H1o, -NC4H8O, -O(CH2)2N(CH3)2, -O(CH2)2NC4H8 and -O(CH2)2NC5Hj0; R2 is a functional group including, but not limited to, hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy (e.g., methoxy, ethoxy, vinyloxy, ethynyloxy, cyclopropyloxy, etc.), acyloxy (e.g., formyloxy, acetoxy, propionyloxy, heptanoyloxy, glycinate, etc.), alkylcarbonate, cypionyloxy, S-alkyl, -SCN, S-acyl and -OC(O)R6, wherein R6 is a functional group including, but not limited to, alkyl (e.g., methyl, ethyl, etc.), alkoxyalkyl (e.g., -CH2OCH3) and alkoxy (-OCH3);
R3 is a functional group including, but not limited to, alkyl, hydroxy, alkoxy and acyloxy;
R4 is a functional group including, but not limited to, hydrogen and alkyl;
and X is a functional group including, but not limited to, =0 and =N-OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl, with the proviso that when R] is N(CH3)2, R2 is methoxy, R3 is acetoxy, R4 is methyl and X is =0, the salt is not an HC1 or an HBr salt.
[00121 Thus, compositions of the present invention comprise a compound of general formula I which is capable of forming a salt when the compound is reacted with a suitable acid. Preferably, a compound of general formula I comprises a basic functional group attached at the 4 position of the phenyl group located at the 11(3 position of the compound (i.e., the R' position); however, compounds of general formula I comprising a basic functional group attached at any position are within the scope of the invention so long as a salt of the compound may be prepared. In addition to the basic functional groups listed above, other suitable basic functional groups for R' upon which a salt may be prepared include, without limitation, methylamine, dimethylamine, ethylamine, diethylamine, ethylmethylamine, isopropylamine, diisopropylamine, n-butylamine, ethanolamine, diethanolamine, methylethanolamine, isopropanolamine, diisopropanolamine, ethyleneimine, ethylenediamine, pyridine and morpholine functional groups.
100131 The term "alkyl" refers to a branched, unbranched, monovalent hydrocarbon radical having from 1-12 carbons. When the alkyl group has from 1-6 carbon atoms, it may be referred to as a "lower alkyl." Representative alkyl radicals include, for example, methyl, ethyl, n-propyl, i-propyl, 2-propenyl (or allyl), n-butyl, t-butyl, i-butyl (or 2-methylpropyl), etc. As used herein, the term alkyl encompasses "substituted alkyls." A substituted alkyl refers to alkyl further containing one or more functional groups such as lower alkyl, aryl, aralkyl, acyl, halogen (i.e., alkylhalos, e.g., CF3), hydroxy (e.g., hydroxymethyl), amino, alkylamino, acylamino, acyloxy, alkoxy (e.g., methoxymethyl), mercapto and the like. These groups may be attached to any carbon atom of the lower alkyl moiety.
[00141 The term "alkoxy" may refer to a -OR group, where R is a lower alkyl, substituted lower alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl. Suitable alkoxy radicals include, for example, methoxy, ethoxy, phenoxy, t-butoxy (e.g., methoxyethoxy, methoxymethoxy, etc.), etc.
[0015] The term "acyloxy" may refer to an organic radical derived from an organic acid by the removal of a hydrogen. The organic radical can be further substituted with one or more functional groups such as alkyl, aryl, aralkyl, acyl, halogen, amino, thiol, hydroxy, alkoxy, etc. An example of such a substituted organic radical is glycinate (e.g., --OC(O)CHzNHz). Suitable acyloxy groups include, for example, acetoxy, i.e., CH3COO-, which may be derived from acetic acid, formyloxy, i.e., H(CO)O-, which may be derived from formic acid and cypionyloxy, which may be derived from 3-cyclopentylpropionic acid.
[0016] The term "halogen" may refer to fluorine, bromine, chlorine and iodine atoms.
The term "hydroxyl" may refer to the group -OH. The term "acyl" may denote groups -C(O)R, where R is alkyl or substituted alkyl, aryl or substituted aryl as defined herein. The term "aryl" may refer to an aromatic substituent which may be a single ring or multiple rings which are fused together, linked covalently, or linked to a common group such as an ethylene or methylene moiety. The aromatic ring(s) may include phenyl, naphthyl, biphenyl, diphenylmethyl, 2,2-diphenyl-l-ethyl, and may contain a heteroatom, such as thienyl, pyridyl and quinoxalyl. The aryl group may also be substituted with halogen atoms, or other groups such as nitro, carboxyl, alkoxy, phenoxy, and the like. Additionally, the aryl group may be attached to other moieties at any position on the aryl radical which would otherwise be occupied by a hydrogen atom (such as 2-pyridyl, 3-pyridyl and 4-pyridyl).
[0017] The term "alkyl carbonate" may refer to the group -OC(O)OR, where R is alkyl, substituted alkyl, aryl, or substituted aryl as defined herein.
[0018] The term "S-alkyl" may refer to the group -SR, where R is lower alkyl or substituted lower alkyl. The term "S-acyl" may refer to a thioester derived from the reaction of a thiol group with an acylating agent. Suitable S-acyls include, for example, S-acetyl, S-propionyl and S-pivaloyl. S-acyl may refer to such thioesters regardless of their method of preparation. The terms "N-oxime" and "N-alkyloxime"
may refer to the group =N-OR5, wherein R5 is, for example, hydrogen (N-oxime) or alkyl (N-alkyloxime). The oximes can consist of the syn-isomer, the anti-isomer or a mixture of both the syn- and anti-isomers.
100191 Representative compounds within Formula I, include those in which R' is --N(CH3)2; those in which R2 is hydrogen, halogen or alkoxy; those in which R3 is acyloxy; those in which R4 is alkyl (e.g., methyl and ethyl); and those in which X is =0 and =N-OR5, wherein R5 is hydrogen or alkyl. Additional compounds include those in which R' is --N(CH3)2; R2 is halogen; R3 is acyloxy; and R4 is alkyl, such where R2 is F, Br or Cl; and R4 is methyl. Also included are compounds in which R' is -N(CH3)2; R2 is alkyl; R3 is acyloxy; R4 is alkyl; and X is =0. Also included are compounds in which R' is --N(CH3)2; R2 is alkoxy; R3 is acyloxy; R4 is alkyl;
and X
is =0. Additional compounds are those in which R 2 is methoxy or ethoxy; and R3 is acetoxy or methoxy. Also included are compounds in which R' is -N(CH3); R 2 is hydroxy; R3 is acyloxy; R4 is alkyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R2 and R3 are both acyloxy; R4 is alkyl; and X is =0.
Additional compounds are those in which R2 and R3 are both acetoxy. Also included are compounds in which R' is -N(CH3)2; R 2 is S-acyl; R3 is hydroxy or acyloxy; R4 is alkyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R
2 is cypionyloxy; R3 is acetoxy; R4 is alkyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R 2 is methoxy; R3 is acetoxy; R4 is alkyl; and X is =0 and =N-ORS, wherein R5 is, for example, hydrogen or alkyl (e.g., methyl, ethyl, etc.).
Also included are compounds in which R' is -N(CH3)2; R2 and R3 are both acetoxy;
R4 is alkyl; and X is =0 and =N-ORS, wherein RS is, for example, hydrogen or alkyl (e.g., methyl, ethyl, etc.).
[0020] Exemplar compounds include, but are not limited to, 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-methoxy-l9-norpregna-4,9(10)-diene-3,20-dione (CDB-4124) with the following structural formula:
i H3 OMe HC~N
3 OAc O
with the proviso that salts of CDB-4124 are not HC1 or HBr acid salts.
100211 Another exemplar compound is 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione (CDB-2914) with the following structural formula:
H C~N
3 OAc O
[0022] Other exemplar compounds include, but are not limited to, 17a-acetoxy-chloro-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione;
17a-acetoxy-2l-bromoro-11 [3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17-,21-diacetoxy-11(3-(4-N,N-dimethylaminophenyl) 19-norpregna-4,9-diene-3,20-dione; 17a-hydroxy-21-acetylthio-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21 -acetylthio-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-ethoxy-11(3-(4N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-methyl-11(3-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione;
17a-acetoxy-21-methoxy-11(3-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21 -ethoxy-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-(3'-cyclopentylpropionyloxy) 11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-hydroxy-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione;
17a,21-diacetoxy-11 [3-(4-N,N-dimethylaminophenyl) 9-norpregna-4,9-diene-3,20-dione 3-oxime; 17a-acetoxy-21-methoxy-11(3-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,2-dione 3-oxime; 17a-acetoxy-11(3-[4-(N-methylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; and 17a,21-diacetoxy-11 [3-[4-(N-methylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione.
[0023] Also included are those compounds in which R' is -N(CH3)2, -NC4H8, --NC4H1 o, -NC4HgO, -O(CH2)2N(CH3)2, -O(CH2)2NC4H8, --O(CH2)2NC3H1 o, and -O(CH2)2NCSHjo; those in which R 2 is hydrogen, alkyloxy, alkoxy, -SAc, -SCN, -OC(O)CH2N(CH3)2, and -OC(O)R6, wherein R6 is a functional group including, but not limited to, alkyls (e.g., -CH2CH3), alkoxy esters (e.g., -CHzOMe) and alkoxys (e.g., -OCH3); those in which R3 is alkyl, alkoxy, acyloxy and hydroxy;
those in which R4 is alkyl (e.g., methyl and ethyl); and those is which X is =0 or =N-OR5, wherein R5 is hydrogen or alkyl. Also preferred are compounds in which R' is -N(CH3)2; R2 is hydrogen; R3 is methoxymethyl; R4 is methyl; and X is =0.
Also included are compounds in which R' is -N(CH3)2; R 2 is hydrogen; R3 is -OC(O)H, -OC(O)CH2CH3 or -OC(O)C6H13; R4 is methyl; and X is =0. Also included are compounds in which R' is -NC4Hs, -NC5H~o, or -NC4HgO; R2 is hydrogen; R3 is acetoxy; R4 is methyl; and X is =0. Also included are compounds in which R' is -N(CH3)2 or NC5Hio; R2 is hydrogen; R3 is methoxy; R4 is methyl;
and X is =0. Also included are compounds in which R' is --NC5Hio; R2 and R3 are both acetoxy; R4 is methyl; and X is =0. Also included are compounds in which R' is -NC5HI o or --O(CH2)2N(CH3)2; R 2 is methoxy; R3 is acetoxy; R4 is methyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R2 is -OC(O)CH2CH3, --OC(O)OCH3, -OC(O)OCH2OCH3, -OCH=CH2, -OC(O)CH2N(CH3)2 or -SCN; R3 is acetoxy; R4 is methyl; and X is =0. Also included are compounds in which Ri is --N(CH3)2; R2 is -OC(O)H; R3 is -OC(O)H; R4 is methyl; and X is =0. Also included are compounds in which R' is -N(CH3)2; R2 is -OC(O)H; R3 is hydroxy; R4 is methyl; and X is =0. Also included are compounds in which R' is -NC5Hlo; R2 is hydrogen; R3 is acetoxy; R4 is methyl; and X is =N-ORS, wherein is hydrogen. Also included are compounds in which R' is -N(CH3)2 or -NC5Hio;
R 2 is hydrogen or methoxy; R3 is methoxy or ethoxy; R4 is methyl; and X is =N-----ORS, wherein RS is hydrogen.
[0024] Exemplar compounds also include, but are not limited to, 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-methoxy-l9-norpregna-4,9(10)-diene-3,20-dione;
17a-formyloxy-11(3-[4-(N,N-diethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-propionoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-heptanoyloxy-11 R-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-methoxymethyl-11(3-[4-N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-(4-N-pyrrolidinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-(4-N-piperidinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-(4-N-morpholinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a-methoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-methoxy-11 P-(4-N-piperidinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a,21-diacetoxy-11(3-(4-N-piperidinophenyl)-norpregna-4,9-diene-3,20-dione; 17a,21-dimethoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a,21-dimethoxy-11(3-(4-N-pyrrolidinophenyl)-19-norpregna-4,9-diene-3,20-dione; 17a,21-dimethoxy-11(3-(4-N-piperidinophenyl) 19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-{4-[2'-(N,N-dimethylamino)ethoxy]phenyl } -21-methoxy-l9-norpregna-4,9-diene-3,20-dione; 17a,21-diformyloxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-propionyloxy-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-(2'-methoxyacetyl)oxy-l9-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-21-hydroxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione-2l-methyl carbonate; 17a-acetoxy-110-[4-(N,N-dimethylamino)phenyl]-21-(1'-ethenyloxy)-19-norpregna-4,9-diene-3,20-dione;
17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-(2'-N,N-dimethylamino)acetoxy-19-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-[4-(N,N-dimethylamino)phenyl]-21-thiocyanato-l9-norpregna-4,9-diene-3,20-dione; 17a-acetoxy-11(3-(4-N-piperidinophenyl)-19-norpregna-4,9-diene-3,20-dione 3-oxime; 17a-methoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione 3-oxime; 17a-methoxy-11 [1-(4-N-piperidinophenyl)-19-norpregna-4,9-diene-3,20-dione 3 -oxime;
and 17a,21-dimethoxy-11(3-[4-(N,N-dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione 3-oxime.
100251 The stability of a compound having general formula I may be significantly increased when the compound is in the form of a salt. A composition is provided comprising a pharmaceutically acceptable salt of a compound of formula I and optionally a pharmaceutically acceptable carrier.
100261 In practice, the use of the salt form inherently amounts to use of the free base form. Accordingly, acids which are suitable to prepare the salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial pharmaceutical effects of these compounds in the free base are not vitiated by side effects ascribable to the anions. The compounds of general formula I may be regenerated from the salts by the application or adaptation of known methods. For example, the compounds can be regenerated from their acid addition salts by treatment with an alkali, e.g., sodium bicarbonate solution.
[0027] The salts can be prepared in situ during the final isolation and purification of a compound of general formula I or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, halide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactiobionate, laurylsulphonate salts and the like (See, for example, S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 66:1-19, 1977, the contents of which are hereby incorporated herein by reference). For example, the salts may be prepared either by dissolving the free base in aqueous or aqueous-alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
[0028] The term "pharmaceutically acceptable salt" refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of general formula I.
[0029] Compositions are provided comprising a pharmaceutically acceptable salt of a compound of general formula I. It is expected that salts of a compound of general formula I will have increased stability relative to an equivalent amount of the free base form of the compound under equivalent conditions. Thus, it is expected that compositions of the instant invention will have increased resistance to chemical modification. The stability of a pharmaceutically acceptable salt of a compound of general formula I may be enhanced by at least 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 percent or more relative to an equivalent amount of the free base form of the same compound under equivalent conditions.
[0030] A typical parameter of stability is shelf life, which is defined as the time period during which a drug product is expected to remain within the approved shelf life specification. Accelerated testing may be performed for a 6-month period at 40 degrees C and 75% relative humidity. Under these conditions, a change in drug concentration of about 5% from the initial assay values is considered significant. It is expected that compositions comprising pharmaceutically acceptable salts of compounds of general formula I will exhibit an increased shelf life relative to equivalent compositions comprising the free base form of the same compounds under equivalent conditions.
[0031] Stability, as used herein, refers to the ability to detect the active ingredient (i.e., a compound of general formula I), in a composition, typically by HPLC, after storage interval under predetermined conditions of temperature and humidity.
Although HPLC is preferred, any method for detecting the active ingredient capable of identifying chemical modification and/or change in concentration of the active ingredient may be used.
[0032] Also provided is a method for increasing the stability of a compound of general formula I by reacting the compound with a suitable acid to form a pharmaceutically acceptable salt.
[0033] The compositions may possess potent antiprogestational activity and minimal antiglucocorticoid activity, combined with improved stability, which may render these compositions suitable for oral administration.
100341 The compositions can be advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningioma; to treat uterine leiomyonas, to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; to induce cervical ripening, for hormone therapy; and for contraception.
[0035] The compositions having antiprogestational activity may also be characterized by antagonizing the effects of progesterone. As such, the compositions may be of particular value in the control of hormonal irregularities in the menstrual cycle, for controlling endometriosis and dysmenorrhea, and for inducing menses. In addition, the compositions can be used as a method of providing hormone therapy either alone or in combination with estrogenic substances in postmenopausal women, or in women whose ovarian hormone production is otherwise compromised.
[0036] Moreover, the compositions can be used for control of fertility during the whole of the reproductive cycle. For long-term contraception, the compositions can be administered either continuously or periodically depending on the dose. In addition, the compositions may be of particular value as post-coital contraceptives, for rendering the uterus inimical to implantation, and as "once a month"
contraceptive agents.
100371 A further important utility for the compositions lies in their ability to slow down growth of hormone-dependent tumors and/or tumors present in hormone-responsive tissues. Such tumors include, but are not limited to, kidney, breast, endometrial, ovarian, and prostate tumors, e.g., cancers, which may be characterized by possessing progesterone receptors. In addition, such tumors include meningiomas.
Other utilities of the compositions include the treatment of fibrocystic disease of the breast and uterine.
100381 The compositions can be administered to any warm-blooded mammal such as humans, domestic pets, and farm animals. Domestic pets include dogs, cats, etc. Farm animals include cows, horses, pigs, sheep goats, etc.
[0039] The amount of active ingredient that can be combined with an optimal carrier material to produce a single dosage form will vary depending upon the disease treated, the mammalian species, and the particular mode of administration. For example, a unit dose may comprise between 0.1 milligram and 1 gram of the active ingredient or between 0.001 and 0.5 grams. However, the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion;
other drugs which have previously been administered; and the severity of the particular disease undergoing therapy.
[0040] The compositions can be administered by a variety of methods. For example, the compositions can be administered via the oral route in a form of solutions, suspensions, emulsions, tablets, including sublingual and intrabuccal tablets, soft gelatin capsules, including solutions used in soft gelatin capsules, aqueous or oil suspensions, emulsions, pills, lozenges, troches, tablets, syrups or elixirs and the like.
[0041] The compositions can be also administered as an implant including SILASTIC
and biodegradable implants or via intramuscular and intravenous injections.
[0042] The compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents. Tablets containing the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients, which are suitable for manufacture of tablets are acceptable. These excipients can be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate, granulating and disintegrating agents, such as maize starch, or alginic acid;
binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid and talc. Tablets can be uncoated or, alternatively, they can be coated by known methods to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay such as glyceryl monostearate or glyceryl distearate alone or with a wax can be employed.
[0043] Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
[0041] The compositions can be also administered as an implant including SILASTIC
and biodegradable implants or via intramuscular and intravenous injections.
[0042] The compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents. Tablets containing the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients, which are suitable for manufacture of tablets are acceptable. These excipients can be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate, granulating and disintegrating agents, such as maize starch, or alginic acid;
binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid and talc. Tablets can be uncoated or, alternatively, they can be coated by known methods to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay such as glyceryl monostearate or glyceryl distearate alone or with a wax can be employed.
[0043] Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
100441 Aqueous suspensions may contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (erg., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e.g. polyoxyethylene sorbitan monooleate). The aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin.
[0045] Oil suspensions can be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents can be added to provide a palatable oral preparation. These compositions can be preserved by the addition of an antioxidant such as ascorbic acid.
[0046] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water can be formulated from the active ingredients in admixture with a dispersing, suspending and/or wetting agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.
[0047] The pharmaceutical composition can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion can also contain sweetening and flavoring agents.
[0048] Syrups and elixirs can be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations can also contain a demulcent, a preservative, a flavoring or a coloring agent.
100491 The pharmaceutical composition can be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
This suspension can be formulated using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3-butanediol.
Among the acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride. In addition, sterile fixed oils can be employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables.
[0045] Oil suspensions can be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents can be added to provide a palatable oral preparation. These compositions can be preserved by the addition of an antioxidant such as ascorbic acid.
[0046] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water can be formulated from the active ingredients in admixture with a dispersing, suspending and/or wetting agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.
[0047] The pharmaceutical composition can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion can also contain sweetening and flavoring agents.
[0048] Syrups and elixirs can be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations can also contain a demulcent, a preservative, a flavoring or a coloring agent.
100491 The pharmaceutical composition can be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
This suspension can be formulated using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3-butanediol.
Among the acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride. In addition, sterile fixed oils can be employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables.
[0050] The compound can also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperatures and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
100511 They can also be administered by in intranasal, intraocular, intravaginal, and intrarectal routes including suppositories, insufflation, powders and aerosol formulations.
[0052] Compounds administered by the topical route can be administered as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
[0053] The invention will be described in greater detail by way of the following specific, but not limiting, example.
Example 1. Formulations of the Instant Invention Can Be Prepared As Tablets.
[0054] To obtain tablets for practicing the instant invention, the following ingredients can be pressed together in a tablet press:
10.0 mg of a pharmaceutically acceptable salt of CDB-4124 140.5 mg of lactose 69.5 mg of corn starch 2.5 mg of poly-N-vinylpyrrolidone 2.0 mg of aerosil 0.5 mg of magnesium stearate [0055] To obtain oily preparations for practicing the instant invention, the following ingredients can be mixed together and loaded into ampoules:
100.0 mg of a pharmaceutically acceptable salt of CDB-4124 343.3 mg of castor oil 608.6 mg of benzyl benzoate Example 2. Formation of the perchloric, methanesulfonic and phosphoric acid salts of CDB-4124 [0056] CDB-4124 was dissolved in one-part acetone and five-parts ethyl acetate and the resulting solution was split into five fractions. To each fraction, either citric acid, mandelic acid, perchloric acid, methanesulfonic acid or phosphoric acid was added in sufficient molar quantity to create the corresponding acid salt of CDB-4124.
The reaction mixtures were stirred for about 2 hours at about 20 C followed by 2 hours below 0 C. The resulting solids were then filtered and washed with cold ethyl acetate and dried.
[0057] The citric and mandelic acid salts were not formed under these conditions.
The perchloric, methanesulfonic and phosphoric acid steroid salts were all prepared in good recovery yields (-90%). It was immediately determined that these acid steroid salts were hygroscopic and required handling in a glove bag with a nitrogen atmosphere. Recrystallizations using various solvent systems (e.g.
ethanol/ethyl ether) were attempted with no success. It was believed that the starting steroid used (90% peak area purity) was not high enough in purity and perhaps was contributing to the difficulty in recrystallization of the acid salts.
[0058] Accordingly, a higher purity yield of CDB-4124 was used for the formation of the methanesulfonic acid salt, by the procedure described above. The methanesulfonic acid salt was successfully recrystallized using an acetone/water solvent system.
100511 They can also be administered by in intranasal, intraocular, intravaginal, and intrarectal routes including suppositories, insufflation, powders and aerosol formulations.
[0052] Compounds administered by the topical route can be administered as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
[0053] The invention will be described in greater detail by way of the following specific, but not limiting, example.
Example 1. Formulations of the Instant Invention Can Be Prepared As Tablets.
[0054] To obtain tablets for practicing the instant invention, the following ingredients can be pressed together in a tablet press:
10.0 mg of a pharmaceutically acceptable salt of CDB-4124 140.5 mg of lactose 69.5 mg of corn starch 2.5 mg of poly-N-vinylpyrrolidone 2.0 mg of aerosil 0.5 mg of magnesium stearate [0055] To obtain oily preparations for practicing the instant invention, the following ingredients can be mixed together and loaded into ampoules:
100.0 mg of a pharmaceutically acceptable salt of CDB-4124 343.3 mg of castor oil 608.6 mg of benzyl benzoate Example 2. Formation of the perchloric, methanesulfonic and phosphoric acid salts of CDB-4124 [0056] CDB-4124 was dissolved in one-part acetone and five-parts ethyl acetate and the resulting solution was split into five fractions. To each fraction, either citric acid, mandelic acid, perchloric acid, methanesulfonic acid or phosphoric acid was added in sufficient molar quantity to create the corresponding acid salt of CDB-4124.
The reaction mixtures were stirred for about 2 hours at about 20 C followed by 2 hours below 0 C. The resulting solids were then filtered and washed with cold ethyl acetate and dried.
[0057] The citric and mandelic acid salts were not formed under these conditions.
The perchloric, methanesulfonic and phosphoric acid steroid salts were all prepared in good recovery yields (-90%). It was immediately determined that these acid steroid salts were hygroscopic and required handling in a glove bag with a nitrogen atmosphere. Recrystallizations using various solvent systems (e.g.
ethanol/ethyl ether) were attempted with no success. It was believed that the starting steroid used (90% peak area purity) was not high enough in purity and perhaps was contributing to the difficulty in recrystallization of the acid salts.
[0058] Accordingly, a higher purity yield of CDB-4124 was used for the formation of the methanesulfonic acid salt, by the procedure described above. The methanesulfonic acid salt was successfully recrystallized using an acetone/water solvent system.
Claims (21)
1. A composition comprising a pharmaceutically acceptable salt of a compound having the general formula:
wherein:
R1 is a basic functional group selected from the group consisting of -N(CH3)2 and -NHCH3;
R2 is a member selected from the group consisting of hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkylcarbonate, cypionyloxy, S-alkyl, -SCN, S-acyl, and -OC(O)R6, wherein R6 is a member selected from the group consisting of alkyl, alkoxy ester and alkoxy;
R3 is a member selected from the group consisting of alkyl-alkoxy, alkoxy and acyloxy;
R4 is a member selected from the group consisting of hydrogen and alkyl;
X is a member selected from the group consisting of =O and =N-OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl; and with the proviso that when R1 is -N(CH3)2, R2 is methoxy, R3 is acetoxy, R4 is methyl and X
is =O, the salt is not an HCl or an HBr salt
wherein:
R1 is a basic functional group selected from the group consisting of -N(CH3)2 and -NHCH3;
R2 is a member selected from the group consisting of hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkylcarbonate, cypionyloxy, S-alkyl, -SCN, S-acyl, and -OC(O)R6, wherein R6 is a member selected from the group consisting of alkyl, alkoxy ester and alkoxy;
R3 is a member selected from the group consisting of alkyl-alkoxy, alkoxy and acyloxy;
R4 is a member selected from the group consisting of hydrogen and alkyl;
X is a member selected from the group consisting of =O and =N-OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl; and with the proviso that when R1 is -N(CH3)2, R2 is methoxy, R3 is acetoxy, R4 is methyl and X
is =O, the salt is not an HCl or an HBr salt
2. The composition of claim 1, wherein R1 is -N(CH3)2.
3. The composition of claim 2, wherein the compound is selected from the group consisting of: 17.alpha.-acetoxy-11.beta.-[4-(N,N-dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9(10)-diene-3,20-dione; and 17.alpha.-acetoxy-11.beta.-[4-(N,N-dimethylamino)phenyl]-21-acetoxy-19-norpregna-4,9(10)-diene-3,20-dione.
4. The composition of claim 3, wherein the compound is 17.alpha.-acetoxy-11.beta.-[4-(N,N-dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9(10)-diene-3,20-dione.
5. The composition of claim 1, wherein R1 is -NHCH3
6. The composition of claim 5, wherein the compound is selected from the group consisting of: 17.alpha.-acetoxy-11.beta.-[4-(N-methylamino)phenyl]-21-methoxy-norpregna-4,9(10)-diene-3,20-dione; and 17.alpha.-acetoxy-11.beta.-[4-(N-methylamino)phenyl]-21-acetoxy-19-norpregna-4,9(10)-diene-3,20-dione.
7. The composition of claim 6, wherein the compound is 17.alpha.-acetoxy-11.beta.-[4-(N-methylamino)phenyl]-21-methoxy-19-norpregna-4,9(10)-diene-3,20-dione.
8. The composition of claim 3, wherein the salt is the perchloric, methanesulfonic or phosphoric acid salt of said compound.
9. The composition of claim 8, wherein the salt is the methanesulfonic salt.
10. The composition of claim 5 or 6, wherein the salt is the HCl or HBr salt.
11. Use of the composition of any one of claims 3, 6 or 7 for producing an antiprogestational effect in a patient.
12. Use of the composition of any one of claims 3, 6 or 7 for inducing menses in a patient.
13. Use of the composition of any one of claims 3, 6 or 7 for treating endometriosis in a patient.
14. Use of the composition of any one of claims 3, 6 or 7 for treating dysmenorrhea, in a patient.
15. Use of the composition of any one of claims 3, 6 or 7 for treating endocrine hormone-dependent tumors in a patient.
16. Use of the composition of any one of claims 3, 6 or 7 for treating meningiomas in a patient.
17. Use of the composition of any of claims 3, 6 or 7 for treating uterine fibroids in a patient.
18. Use of the composition of any of claims 3, 6 or 7 for inhibiting uterine endometrial proliferation in a patient.
19. Use of the composition of any of claims 3, 6 or 7 for inducing labor in a patient.
20. Use of the composition of any of claims 3, 6 or 7 as a contraceptive.
21. A capsule or tablet for oral use, comprising a composition according to claims 3, 6 or 7.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88536307P | 2007-01-17 | 2007-01-17 | |
US60/885,363 | 2007-01-17 | ||
PCT/US2008/050128 WO2008088935A2 (en) | 2007-01-17 | 2008-01-03 | Pharmaceutically acceptable salts of 11- (4-aminophenyl) -19-n0rpregna-4,9 (10) -diene-3, 20-dione derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2674440A1 true CA2674440A1 (en) | 2008-07-24 |
Family
ID=39387140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002674440A Abandoned CA2674440A1 (en) | 2007-01-17 | 2008-01-03 | Methods for improved stability of steroid derivatives |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP2125858A2 (en) |
JP (1) | JP2010516686A (en) |
KR (1) | KR20090105944A (en) |
CN (1) | CN101616926A (en) |
AR (1) | AR064947A1 (en) |
AU (1) | AU2008206599A1 (en) |
BR (1) | BRPI0806572A2 (en) |
CA (1) | CA2674440A1 (en) |
CL (1) | CL2008000138A1 (en) |
CR (1) | CR10924A (en) |
EA (1) | EA200970692A1 (en) |
EC (1) | ECSP099537A (en) |
IL (1) | IL199684A0 (en) |
MX (1) | MX2009007313A (en) |
TW (1) | TW200835503A (en) |
WO (1) | WO2008088935A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI477276B (en) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | Antiprogestin dosing regimens |
US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
HUP0900171A2 (en) * | 2009-03-20 | 2010-12-28 | Richter Gedeon Nyrt | Novel crystal form of 17-acetoxy-11-[4-(dimethyl-amino)-phenyl]-21-metoxy-19-norpregna-4,9-dien-3,20-dione and process for it's preparation |
HUP0900487A2 (en) | 2009-08-05 | 2011-03-28 | Richter Gedeon Nyrt | Novel crystal polymorphic form of 17-acetoxy-11 -[4-(dimethylamino)phenyl]-21-methoxy-4,9-diene-3,20-dione and process for it's preparation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA8231B (en) * | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
US6020328A (en) * | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
US8044223B2 (en) * | 2003-04-04 | 2011-10-25 | Bridge Organics Co. | Crystalline 19-norsteroids |
-
2008
- 2008-01-03 CA CA002674440A patent/CA2674440A1/en not_active Abandoned
- 2008-01-03 AU AU2008206599A patent/AU2008206599A1/en not_active Abandoned
- 2008-01-03 CN CN200880002367A patent/CN101616926A/en active Pending
- 2008-01-03 EA EA200970692A patent/EA200970692A1/en unknown
- 2008-01-03 WO PCT/US2008/050128 patent/WO2008088935A2/en active Application Filing
- 2008-01-03 BR BRPI0806572-1A patent/BRPI0806572A2/en not_active IP Right Cessation
- 2008-01-03 KR KR1020097015532A patent/KR20090105944A/en not_active Application Discontinuation
- 2008-01-03 EP EP08713475A patent/EP2125858A2/en not_active Withdrawn
- 2008-01-03 JP JP2009546454A patent/JP2010516686A/en not_active Withdrawn
- 2008-01-03 MX MX2009007313A patent/MX2009007313A/en not_active Application Discontinuation
- 2008-01-15 TW TW097101566A patent/TW200835503A/en unknown
- 2008-01-17 AR ARP080100217A patent/AR064947A1/en unknown
- 2008-01-17 CL CL200800138A patent/CL2008000138A1/en unknown
-
2009
- 2009-07-02 IL IL199684A patent/IL199684A0/en unknown
- 2009-07-14 CR CR10924A patent/CR10924A/en not_active Application Discontinuation
- 2009-07-23 EC EC2009009537A patent/ECSP099537A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008206599A1 (en) | 2008-07-24 |
AR064947A1 (en) | 2009-05-06 |
IL199684A0 (en) | 2010-04-15 |
EA200970692A1 (en) | 2010-02-26 |
BRPI0806572A2 (en) | 2014-05-06 |
ECSP099537A (en) | 2009-08-28 |
CL2008000138A1 (en) | 2008-05-16 |
WO2008088935A3 (en) | 2009-03-05 |
CR10924A (en) | 2009-10-30 |
KR20090105944A (en) | 2009-10-07 |
CN101616926A (en) | 2009-12-30 |
MX2009007313A (en) | 2009-07-15 |
TW200835503A (en) | 2008-09-01 |
EP2125858A2 (en) | 2009-12-02 |
JP2010516686A (en) | 2010-05-20 |
WO2008088935A2 (en) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090149434A1 (en) | Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride | |
AU2017251837B2 (en) | Compositions and Methods for Non-Toxic Delivery of Antiprogestins | |
CA2672888A1 (en) | Methods and formulations for improved bioavailability of antiprogestins | |
CA2674440A1 (en) | Methods for improved stability of steroid derivatives | |
JP2016180004A (en) | Novel 19-norsteroids for treating progesterone dependent conditions and use methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |